JP2018513150A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513150A5
JP2018513150A5 JP2017553109A JP2017553109A JP2018513150A5 JP 2018513150 A5 JP2018513150 A5 JP 2018513150A5 JP 2017553109 A JP2017553109 A JP 2017553109A JP 2017553109 A JP2017553109 A JP 2017553109A JP 2018513150 A5 JP2018513150 A5 JP 2018513150A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
enantiomer
solvate
diastereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017553109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513150A (ja
JP6617155B6 (ja
JP6617155B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/078703 external-priority patent/WO2016161952A1/zh
Publication of JP2018513150A publication Critical patent/JP2018513150A/ja
Publication of JP2018513150A5 publication Critical patent/JP2018513150A5/ja
Priority to JP2019203698A priority Critical patent/JP6928774B2/ja
Application granted granted Critical
Publication of JP6617155B2 publication Critical patent/JP6617155B2/ja
Publication of JP6617155B6 publication Critical patent/JP6617155B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017553109A 2015-04-07 2016-04-07 チロシンキナーゼ阻害剤およびそれを含む医薬組成物 Active JP6617155B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019203698A JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510161674.4 2015-04-07
CN201510161674 2015-04-07
PCT/CN2016/078703 WO2016161952A1 (zh) 2015-04-07 2016-04-07 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019203698A Division JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Publications (4)

Publication Number Publication Date
JP2018513150A JP2018513150A (ja) 2018-05-24
JP2018513150A5 true JP2018513150A5 (enExample) 2018-08-02
JP6617155B2 JP6617155B2 (ja) 2019-12-11
JP6617155B6 JP6617155B6 (ja) 2020-01-22

Family

ID=57072288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553109A Active JP6617155B6 (ja) 2015-04-07 2016-04-07 チロシンキナーゼ阻害剤およびそれを含む医薬組成物
JP2019203698A Active JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019203698A Active JP6928774B2 (ja) 2015-04-07 2019-11-11 チロシンキナーゼ阻害剤およびそれを含む医薬組成物

Country Status (5)

Country Link
US (1) US10654808B2 (enExample)
EP (1) EP3293177B1 (enExample)
JP (2) JP6617155B6 (enExample)
CN (3) CN106046007B (enExample)
WO (1) WO2016161952A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4023640A1 (en) * 2015-12-25 2022-07-06 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
EP3521276B1 (en) * 2016-09-30 2021-03-10 Guangdong Raynovent Biotech Co., Ltd. Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
US10800741B2 (en) 2017-02-07 2020-10-13 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Quinoline compound, preparation method and medical use therefor
CN107115344B (zh) * 2017-03-23 2019-06-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途
KR102327054B1 (ko) * 2017-08-29 2021-11-17 기초과학연구원 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도
AU2018325445A1 (en) * 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
WO2019062637A1 (zh) * 2017-09-28 2019-04-04 南京明德新药研发股份有限公司 喹啉衍生物及其作为酪氨酸激酶抑制剂的应用
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CN110483482A (zh) 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN110590839B (zh) * 2018-06-13 2022-04-05 四川海思科制药有限公司 一种乐伐替尼衍生物及制备方法和用途
CN110862397A (zh) * 2018-08-27 2020-03-06 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN109485620A (zh) * 2018-12-26 2019-03-19 安徽工大化工科技有限公司 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法
MX2021009269A (es) * 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
AU2020271855B2 (en) * 2019-04-12 2025-11-27 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
CN111892536B (zh) * 2019-05-05 2022-06-28 北京福元医药股份有限公司 取代的喹啉甲酰胺类化合物及其用途
WO2020249096A1 (zh) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
PL4010330T3 (pl) * 2019-08-08 2026-03-16 Hirundo Biosciences Pochodne chinoliny jako inhibitory kinazy białkowej
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
CN113321654B (zh) * 2020-02-28 2022-05-03 上海济煜医药科技有限公司 作为激酶抑制剂的稠合吡啶酮类化合物
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2023185638A1 (zh) * 2022-03-29 2023-10-05 广东众生睿创生物科技有限公司 一种喹啉衍生物的晶型及其制备方法
CN115215799B (zh) * 2022-08-12 2024-05-31 上海爱博医药科技有限公司 脲类多靶点酪氨酸激酶抑制剂及其多种医药应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252054C (zh) * 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
WO2002012226A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
WO2005021554A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
US7626030B2 (en) * 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CN1993130B (zh) 2004-06-28 2010-06-23 布里斯托尔-迈尔斯斯奎布公司 用于制备稠合杂环激酶抑制剂的方法和中间体
WO2006125597A1 (en) * 2005-05-24 2006-11-30 Unilever N.V. Toothbrush
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
KR101464385B1 (ko) * 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
JP4667537B2 (ja) * 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
EP2550266B1 (en) * 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
CN102958523B (zh) * 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
JPWO2014098176A1 (ja) * 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN106255499A (zh) * 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2016526558A5 (enExample)
JP2016006096A5 (enExample)
JP2019537570A5 (enExample)
JP2013519632A5 (enExample)
JP2004516314A5 (enExample)
JP2015537020A5 (enExample)
JP2017520613A5 (enExample)
JP2012532874A5 (enExample)
JP2006514012A5 (enExample)
JP2016501221A5 (enExample)
JP2016515561A5 (enExample)
JP2020507589A5 (enExample)
JP2009514870A5 (enExample)
JP2009504764A5 (enExample)
JP2016530259A5 (enExample)
JP2008501000A5 (enExample)
JP2010523522A5 (enExample)
JP2015536964A5 (enExample)
JP2020532545A5 (enExample)
JP2014503574A5 (enExample)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
JP2008510770A5 (enExample)
JP2015511609A5 (enExample)
JP2020097577A5 (enExample)